News

The move will help the company to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later in 2014. Interim results for the existing AMD

The seventh ANDA filing was in connection with a current development, supply and marketing agreement with Impax Laboratories. The deal designates IGI Laboratories as the developer, manufacturer and

The patent covers methods for treating ulcerative colitis or Crohn’s disease using placenta-derived cells. This patent has already been issued to Pluristem in South Africa and is currently

Upon the successful closing of the tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly

The tablet formulation of oral CR845 was formulated utilizing Enteris’ proprietary oral delivery technology under a Manufacturing and Clinical Supply Agreement. The agreement with Cara Therapeutics is representative

This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016

The drug addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized as a serious public health threat by the US Centers

The Carbapenem Resistance Consortium aims to develop a rapid diagnostic test, which can target multi-drug resistant pathogens and support the appropriate use of antibiotics. Xpert Carba-R, which is

MGD006 is a humanized, Dual-Affinity Re-Targeting (DART(R)) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. The study,